<?xml version="1.0" encoding="UTF-8"?>
<p>The study population included patients ≥60 years old with newly diagnosed, pathologically confirmed AML, as defined by World Health Organization criteria.
 <sup>
  <xref rid="b13-1031308" ref-type="bibr">13</xref>
 </sup> Patients with an antecedent hematologic disorder or therapy-related myeloid neoplasm were included, but those with acute promyelocytic leukemia or favorable risk cytogenetics according to the European LeukemiaNet (ELN) criteria were excluded from participation.
 <sup>
  <xref rid="b14-1031308" ref-type="bibr">14</xref>
 </sup> Patients with a history of prior treatment with either decitabine or plerixafor, and those undergoing active treatment for a concomitant malignancy were also excluded. There were no mandatory requirements for organ system function or performance status, but patients with a calculated CrCl of ≤50 mL/min using the Cockcroft-Gault formula had a dose reduction of plerixafor by one-third during that cycle, as per the FDA package insert for plerixafor.
</p>
